Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Platelet-rich plasma may help restore immune balance in bald patches, but its effectiveness in treating hair loss is limited.

Psychological therapies can improve wellbeing in people with hair loss.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

A young child with complete hair loss improved significantly with a combination of hair growth treatments and laser therapy.

Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.

Stopping and restarting JAK inhibitors during pregnancy in women with alopecia areata leads to hair loss and regrowth, with most pregnancies resulting in healthy babies.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

The machine learning model effectively assesses the severity of hair loss and could help dermatologists with treatment decisions.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Deucravacitinib helped a man regrow hair significantly.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

The Cross-section Trichometer is a new tool that can measure hair quantity and detect hair loss and growth.

The AI system HairComb accurately scores hair loss severity, matching dermatologist assessments.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

New tools help doctors better assess and treat alopecia areata in kids by considering more than just hair loss.

Trichoscopy is a quick, cost-effective tool for diagnosing different hair loss conditions.

LiPADI is a useful tool for monitoring the severity and treatment of lichen planus.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

Bimatoprost may help treat hair loss from alopecia areata.

Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.